Literature DB >> 9830576

Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure.

S A Jenkins1, D M Nott, J N Baxter.   

Abstract

In healthy subjects octreotide is largely metabolised by the liver suggesting that the plasma half-life of the somatostatin analogue may be prolonged in patients with hepatic dysfunction. The aim of this study was therefore (a) to determine the pharmacokinetics of octreotide following its subcutaneous injection in 6 patients with cirrhosis and portal hypertension and (b) compare the magnitude and duration of the effects of intravenous administration of 250 micrograms somatostatin and 50 micrograms octreotide on corrected wedged hepatic venous pressure (WHVP) and to relate the findings to the plasma levels of the analogue 1 h after administration in 13 patients with cirrhosis and portal hypertension. Following subcutaneous administration of 50 micrograms octreotide the circulating half life (range 2.4 to 4.79 h) was prolonged whereas the clearance (range 2.101 to 4.775 L/h) was decreased compared to healthy controls. Intravenous bolus administration of 250 micrograms somatostatin or 50 micrograms octreotide resulted in a reduction in WHVP of approximately the same magnitude and duration despite appreciable quantities of the analogue in the blood 1 h after administration (1944 +/- 226 pg/ml). These results indicate that the circulating half-life of octreotide is prolonged in cirrhotics suggesting that the dosage regimens should be modified in such patients to avoid accumulation of the analogue in the blood which may result in undesirable side-effects or toxicity. Furthermore, since the magnitude and duration of the reduction in WHVP elicited by IV octreotide is similar to that observed with somatostatin, the analogue, like the native hormone, must be administered by continuous IV infusion to produce a sustained response and hence a therapeutic effect in the management of acute variceal bleeding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830576      PMCID: PMC2423925          DOI: 10.1155/1998/17436

Source DB:  PubMed          Journal:  HPB Surg        ISSN: 0894-8569


  4 in total

Review 1.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

2.  Acute esophageal variceal bleeding: Current strategies and new perspectives.

Authors:  Salvador Augustin; Antonio González; Joan Genescà
Journal:  World J Hepatol       Date:  2010-07-27

3.  Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.

Authors:  J Cebon; M Findlay; C Hargreaves; M Stockler; P Thompson; M Boyer; S Roberts; A Poon; A M Scott; V Kalff; G Garas; A Dowling; D Crawford; J Ring; R Basser; A Strickland; G Macdonald; M Green; A Nowak; B Dickman; H Dhillon; V Gebski
Journal:  Br J Cancer       Date:  2006-09-05       Impact factor: 7.640

Review 4.  Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension.

Authors:  Erwin Biecker
Journal:  ISRN Hepatol       Date:  2013-07-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.